|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | |  |  | | --- | --- | | **Surname** | **Patient I.d.No.** | | **Forename** | **D.O.B. DDMMYYYY** | | **Address** | **NHS No.** | |  | **Sex. Male/Female** | |  |  | |  |  | | **Postcode** |  |   Affix patient identification label in box below or complete details |
| **LUTATHERATherapy for the treatment of Metastatic Neuroendocrine Tumors**  **Eligibility assessment tool** |

**The below document has been adapted, with permission, from Newcastle upon Tyne Hospitals NHS Foundation Trust. Centres should refer to the SMPC for LUTHATHERA® (lutetium [177Lu] oxodotreotide) when preparing their own pro-forma guidance and ensure all requirements are fulfilled prior to product administration.**

[**Click here**](https://www.rlthub.co.uk/sites/rlthub.co.uk/files/NET-PI-reel.pdf) **to access Prescribing information for all Advanced Accelerator Applications**

**and Novartis products mentioned in this material**

LUTATHERA is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP NETs) in adults

1. GEP-NET G1 or G2 Y/N
2. Location of primary ……………………………
3. Disease is metastatic or inoperable Y/N
4. SSR +ve on imaging (Tektrotyd/octreo/68Ga-DOTATOC) Y/N Date of scan
5. CT or MRI showing progression of disease within 3 years Y/N

Modality ………………………………….

Date of scan ………………………………….

Location of progression …………………………………….

1. Cancer related PS 0-2 0 1 2
2. Current use of analogues? Y/N

Type Dose and frequency

Date of last analogue administration ………………………………..

**Adverse Event Reporting**

**Adverse events should be reported. Reporting forms and information can be found at** [**www.mhra.gov.uk/yellowcard**](http://www.mhra.gov.uk/yellowcard)**. Adverse events should also be reported to Novartis via** [**uk.patientsafety@novartis.com**](mailto:uk.patientsafety@novartis.com) **or online through the pharmacovigilance intake (PVI) tool at** [**www.novartis.com/report**](http://www.novartis.com/report)

**If you have a question about the product, please contact Medical Information on 01276 698370 or   
by email at** [**medinfo.uk@novartis.com**](mailto:medinfo.uk@novartis.com)

This material was developed by Advanced Accelerator Applications, a Novartis company. Advanced Accelerator Applications products are discussed herein.